psalexa
logo

Obesity Therapeutics Pipeline Analysis

Obesity Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11252
Available Format:

Obesity, also known as adiposity, is a condition in which unhealthy amount of fat deposition occurs in the body. Obesity is characterized by an increment of amount and size of fat cells in the body. The medical professionals measure waist circumference and body mass index for diagnosis of obesity and overweight. There are many complications associated with obesity such as high blood pressure, metabolic syndrome, atherosclerosis, diabetes, heart disease, cancer, high blood cholesterol, and sleep disorders. The risk factors associated with obesity include unhealthy lifestyle habits such as lack of physical activity, unhealthy eating, not enough sleep, and high amount of stress, age, and family history. Rhythm Pharmaceuticals, Inc. is in the process of developing setmelanotide as a melanocortin type 4 receptor agonist for the treatment of obesity. Vanderbilt University is in the process of developing exenatide as a glucagon like peptide I receptor agonist for the treatment of obesity. Some of the companies having the pipeline of obesity include Rhythm Pharmaceuticals, Inc., Novo Nordisk A/S, Novartis AG, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry